Treatment of ADHD
This free, CME-certified webinar helps you provide the best possible care to children and adolescents with ADHD. Pediatric primary care providers (PCPs) assess and treat the majority of young patients who have ADHD. This makes early diagnosis and treatment of ADHD important in primary care settings. Undertreatment of ADHD can have significant personal and societal impacts. Barriers to treatment include poor adherence, treatment resistance, adverse medication effects, and more. The content of this webinar focuses on multiple treatment strategies for ADHD with stimulants, nonstimulants, and other medications, treatment of comorbidities such as ODD, conduct disorder, anxiety, depression, and bipolar disorder, and relative effect sizes of treatment options and when to choose one versus another. This webinar is presented by Project TEACH, a program funded by the New York State Office of Mental Health.
This program is intended for:
- Primary Care and Family Practice Physicians
- Nursing Professionals
- Other Mental Health, Primary Care and Pediatric Clinicians
At the end of this activity, participants should be able to:
- Describe the multiple options available for the treatment of ADHD with stimulants, nonstimulants, and other classes of medication.
- Identify the effects of treatment of ADHD on co-morbid conditions such as ODD, Conduct Disorder, Anxiety, Depression, and Bipolar Disorder.
- Discuss relative effect sizes of the stimulants and nonstimulants and to provide a rationale for when to choose one versus another.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
David H. Rubin, MD, reviewer
Jane Pimental, MPH
In accord with the disclosure policy of McLean Hospital as well as guidelines set forth by the Accreditation Council on Continuing Medical Education, all people in control of educational content, including speakers, course directors, planners, and reviewers, have been asked to disclose all relevant financial relationships with commercial interests of both themselves and their spouses/partners over the past 12 months, as defined below:
The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org.
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
Relevant financial relationships
ACCME focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
Conflict of Interest
Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.
The following planners, speakers, and content reviewers, on behalf of themselves and their spouse or partner, have reported financial relationships with an entity producing, marketing, re-selling, or distributing health care goods or services (relevant to the content of this activity) consumed by, or used on, patients:
Joseph Biederman, MD, speaker
Research support: Headspace, Lundbeck, Neurocentria Inc., PamLab, Shire Pharmaceuticals Inc., Sunovion, Pfizer Pharmaceuticals, Roche TCRC Inc.
Financial interest (consultant): Avekshan LLC (reviewed and managed by MGH and Partners Healthcare in accordance with their conflict of interest policies)
Consulting fees (consultant and/or advisory board): Aevi Genomics, Akili, Alcobra, Guidepoint, Ironshore, Medgenics, Piper Jaffray, Shire
Royalties paid to Department of Psychiatry at MGH (licensing copyrights rating scale used for ADHD diagnoses): Bracket Global, Ingenix, Prophase, Shire, Sunovion, Theravance
All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have, on behalf of themselves and their spouse or partner, reported no financial relationships related to the content of this activity.
Optimal System Configuration
Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher
Windows PC: 500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh: Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit